AstraZeneca awaiting Seroquel XR approval

Share this article:
AstraZeneca hopes the approval of a once daily version of its blockbuster schizophrenia drug Seroquel can break its streak of bad product news. The FDA is scheduled to make a decision on Seroquel XR on May 17. Many analysts believe the agency’s ruling on the drug could be a positive one. Seroquel XR’s approval could offer the company a chance to show it can still deliver, following recent failures of new drugs to treat stroke and heart disease, which came on the heels of earlier setbacks. “We believe these things can have a significant impact on our business, CEO David Brennan told Reuters in an interview in late April. “Our life cycle management programs have been excellent…we’ve done well in showing we can add incremental value to existing products.” Seroquel had sales of $3.4 billion last year and was AstraZeneca’s second biggest seller. The original immediate formulation of the drug, however, faces patent threats, with a case potentially coming to court next year in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.